1
Kevin Rodzinak
Jeannie M Arruda, Brian T Campbell, Nicholas D P Cosford, Jacob M Hoffman, Essa H Hu, Mark E Layton, Yiwei Li, Jun Liang, Kevin J Rodzinak, Tony Siu, Brian A Stearns, Lida R Tehrani, Mark T Bilodeau, Peter J Manley: Inhibitors of Akt activity. Merck Sharp & Dohme, Matthew A Leff, David A Muthard, March 22, 2011: US07910561 (1 worldwide citation)

The present invention is directed to compounds which contain substituted naphthyridines which inhibit the activity of Akt, a serine/threonine protein kinase. The invention is further directed to chemotherapeutic compositions containing the compounds of this invention and methods for treating cancer ...


2
Kevin Rodzinak
Jeannie M Arruda, Brian T Campbell, Nicholas DP Cosford, Jacob M Hoffman, Essa H Hu, Mark E Layton, Yiwei Li, Jun Liang, Kevin J Rodzinak, Tony Siu, Brian A Stearns, Lida R Tehrani, Mark T Bilodeau, Peter J Manley: Inhibitors of Akt Activity. Merck And Co, November 20, 2008: US20080287457-A1

The present invention is directed to compounds which contain substituted naphthyridines which inhibit the activity of Akt, a serine/threonine protein kinase. The invention is further directed to chemotherapeutic compositions containing the compounds of this invention and methods for treating cancer ...


3
Mark T Bilodeau, April M Cunningham, Randall W Hungate, Timothy J Koester: Tyrosine kinase inhibitors. Merck & Co, J Antonio Garcia Rivas, Mark R Daniel, December 19, 2000: US06162804 (62 worldwide citation)

The present invention relates to benzinidazole compounds which inhibit tyrosine kinase enzymes, compositions which contain tyrosine kinase inhibiting compounds and methods of using tyrosine kinase inhibitors to treat tyrosine kinase-dependent diseases/conditions such as angiogenenesis, cancer, ather ...


4
Nigel J Liverton, David A Claremon, John W Butcher, Mark T Bilodeau: Substituted imidazoles having cytokine inhibitory activity. Merck & Co, Elliott Korsen, Mark R Daniel, January 12, 1999: US05859041 (51 worldwide citation)

Compounds represented by formula I: ##STR1## are disclosed. .sup.AR represents an aromatic group containing 6-10 atoms; and ##STR2## represents a 4 to 10 membered non-aromatic heterocycle containing at least one N atom, and optionally containing 1-2 additional N atoms and 0-1 O or S atom. A pharmace ...


5
Mark T Bilodeau, Randall W Hungate, April M Cunningham, Timothy J Koester: Angiogenesis inhibitors. Merck & Co, Dianne Brown, Mark R Daniel, October 15, 2002: US06465484 (47 worldwide citation)

The present invention relates to compounds which inhibit tyrosine kinase enzymes, compositions which contain tyrosine kinase inhibiting compounds and methods of using tyrosine kinase inhibitors to treat tryrosine kinase-dependent diseases/conditions such as angiogenenesis, cancer, atherosclerosis, d ...


6
Mark E Fraley, Kenneth L Arrington, Mark T Bilodeau, George D Hartman, William F Hoffman, Yuntae Kim, Randall W Hungate: Tyrosine kinase inhibitors. Merck & Co, J Antonio Garcia Rivas, Mark R Daniel, October 23, 2001: US06306874 (47 worldwide citation)

The present invention relates to compounds which inhibit, regulate and/or modulate tyrosine kinase signal transduction, compositions which contain these compounds, and methods of using them to treat tyrosine kinase-dependent diseases and conditions, such as angiogenesis, cancer, tumor growth, athero ...


7
Mark T Bilodeau, George D Hartman, Peter J Manley, Randall W Hungate, Leonard Rodman: Tyrosine kinase inhibitors. Merck & Co, Dianne Brown, J Antonio Garcia Rivas, Mark R Daniel, July 1, 2003: US06586423 (29 worldwide citation)

The present invention relates to compounds which inhibit, regulate and/or modulate tyrosine kinase signal transduction, compositions which contain these compounds, and methods of using them to treat tyrosine kinase-dependent diseases and conditions, such as angiogenesis, cancer, tumor growth, athero ...


8
Mark T Bilodeau, Randall W Hungate, Richard L Kendall, Ruth Rutledge, Kenneth A Thomas Jr, Robert Rubino, Mark E Fraley: Angiogenesis inhibitors. Merck & Co, J Antonio Garcia Rivas, Mark R Daniel, May 22, 2001: US06235741 (29 worldwide citation)

The present invention relates to compounds which inhibit tyrosine kinase enzymes, compositions which contain tyrosine kinase inhibiting compounds and methods of using tyrosine kinase inhibitors to treat tyrosine kinase-dependent diseases/conditions such as angiogenenesis, cancer, atherosclerosis, di ...


9
Mark T Bilodeau, Mark E Fraley, Randall W Hungate: Tyrosine kinase inhibitors. Merck & Co, J Antonio Garcia Rivas, Mark R Daniel, June 12, 2001: US06245759 (24 worldwide citation)

The present invention relates to pyrazolo-pyrimidinyl compounds which inhibit, regulate and/or modulate tyrosine kinase signal transduction, compositions which contain these compounds, and methods of using them to treat tyrosine kinase-dependent diseases and conditions, such as angiogenesis, cancer, ...


10
Mark T Bilodeau, Mark E Duggan, John C Hartnett, Craig W Lindsley, Peter J Manley, Zhicai Wu, Zhijian Zhao: Inhibitors of Akt activity. Merck & Co, Matthew A Leff, David A Muthard, May 29, 2007: US07223738 (23 worldwide citation)

The present invention is directed to compounds comprising a 2,3-diphenylquinoxaline moiety which inhibit the activity of Akt, a serine/threonine protein kinase. The invention is further directed to chemotherapeutic compositions containing the compounds of this invention and methods for treating canc ...



Click the thumbnails below to visualize the patent trend.